AU2001275339A1 - Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury - Google Patents

Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury

Info

Publication number
AU2001275339A1
AU2001275339A1 AU2001275339A AU7533901A AU2001275339A1 AU 2001275339 A1 AU2001275339 A1 AU 2001275339A1 AU 2001275339 A AU2001275339 A AU 2001275339A AU 7533901 A AU7533901 A AU 7533901A AU 2001275339 A1 AU2001275339 A1 AU 2001275339A1
Authority
AU
Australia
Prior art keywords
identification
bone marrow
progenitor cells
human bone
endothelial progenitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275339A
Inventor
Silviu Itescu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of AU2001275339A1 publication Critical patent/AU2001275339A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
AU2001275339A 2000-06-05 2001-06-05 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury Abandoned AU2001275339A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58744100A 2000-06-05 2000-06-05
US09587441 2000-06-05
PCT/US2001/018399 WO2001094420A1 (en) 2000-06-05 2001-06-05 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury

Publications (1)

Publication Number Publication Date
AU2001275339A1 true AU2001275339A1 (en) 2001-12-17

Family

ID=24349821

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275339A Abandoned AU2001275339A1 (en) 2000-06-05 2001-06-05 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury

Country Status (7)

Country Link
US (6) US20040131585A1 (en)
EP (2) EP2324839B1 (en)
JP (3) JP5414958B2 (en)
AU (1) AU2001275339A1 (en)
CA (2) CA2810249A1 (en)
MX (1) MXPA02012067A (en)
WO (1) WO2001094420A1 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10281478B2 (en) 2000-04-06 2019-05-07 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20070111935A1 (en) * 2000-04-06 2007-05-17 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20050277576A1 (en) * 2000-04-06 2005-12-15 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US7291597B2 (en) * 2000-04-06 2007-11-06 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
US9694038B2 (en) 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US7368425B2 (en) * 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
CA2810249A1 (en) * 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20020061587A1 (en) 2000-07-31 2002-05-23 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002022163A1 (en) * 2000-09-13 2002-03-21 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
ES2742730T3 (en) 2001-07-31 2020-02-17 Genzyme Corp Progenitor cell / mother cell mobilization methods
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
JP2005514062A (en) 2001-12-21 2005-05-19 イミュネックス・コーポレーション Endothelial stem cells, cell populations, methods for isolating and using the cells
AU2003224712A1 (en) * 2002-03-21 2003-10-08 University Of Florida Modulating angiogenesis
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
EP1583422B1 (en) * 2002-12-05 2016-03-30 Case Western Reserve University Cell-based therapies for ischemia
WO2004082703A1 (en) * 2003-03-20 2004-09-30 Keiichi Fukuda Combined use of g-csf with angiogenetic factor
KR20060018851A (en) * 2003-05-16 2006-03-02 교와 핫꼬 고교 가부시끼가이샤 Preventive and/or remedy for diseases accompanied by tissue destruction
DE10333901A1 (en) * 2003-07-21 2005-03-10 Transtissue Technologies Gmbh Use of chemokines to recruit human mesenchymal progenitor cells for the regeneration of joint defects
EP1527785A1 (en) * 2003-10-27 2005-05-04 Ludwig-Maximilians-Universität München Use of G-CSF for treating ischemia
GB0329449D0 (en) * 2003-12-19 2004-01-28 Omnicyte Ltd Stem cells
TW200605910A (en) 2004-04-30 2006-02-16 Orbus Medical Technologies Inc Medical device with coating for capturing genetically-altered cells and methods for using same
WO2005113749A2 (en) * 2004-05-14 2005-12-01 Becton, Dickinson And Company Stem cell populations and methods of use
WO2006020954A1 (en) * 2004-08-13 2006-02-23 Medtronic, Inc. Isolation of endothelial progenitor cell subsets and methods for their use
WO2006055743A2 (en) * 2004-11-18 2006-05-26 Franco, Wayne Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs
EP2441461B1 (en) * 2005-11-07 2014-05-07 Amorcyte, Inc. Compositions and methods of vascular injury repair
US20110076255A1 (en) 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
US8637005B2 (en) 2005-11-07 2014-01-28 Amorcyte, Inc. Compositions and methods of vascular injury repair
WO2007093412A2 (en) 2006-02-16 2007-08-23 Fondazione Centro San Raffaele Del Monte Tabor Skeletal muscle periangioblasts and cardiac mesoangioblasts, method for isolation and uses thereof
TW200734462A (en) 2006-03-08 2007-09-16 In Motion Invest Ltd Regulating stem cells
WO2008063753A1 (en) * 2006-10-03 2008-05-29 Medtronic, Inc. Endothelial progenitor cell compositions and neovascularization
US7696309B2 (en) * 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2008085229A2 (en) * 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
WO2008107422A1 (en) * 2007-03-02 2008-09-12 National University Of Ireland, Galway Osteopontin for the prediction and treatment of cardiovascular diseases
CA2682469A1 (en) 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
US8496926B2 (en) * 2007-04-16 2013-07-30 Biocardia, Inc. Treatment for chronic myocardial infarction
MX2010001307A (en) * 2007-08-02 2010-07-30 Novimmune Sa Anti-rantes antibodies and methods of use thereof.
RU2612388C2 (en) * 2007-08-06 2017-03-09 Ноксон Фарма Аг Sdf-1 binding nucleic acids and use thereof
RU2499599C2 (en) 2007-09-28 2013-11-27 Интрексон Корпорейшн Therapeutic gene switching constructs and bioreactors for expressing biotherapeutic molecules and using them
CA2743184A1 (en) 2007-11-09 2009-05-14 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
EP2227238A2 (en) 2007-11-30 2010-09-15 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
EP2225362A1 (en) 2007-11-30 2010-09-08 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
AU2008338525B2 (en) * 2007-12-14 2015-04-02 Juventas Therapeutics, Inc. Compositions and methods of promoting wound healing
GB0818725D0 (en) 2008-10-13 2008-11-19 Habib Nagy A Pharmaceutical composition
CN102245189B (en) * 2008-12-03 2015-06-17 阿莫塞特公司 Infarct area perfusion-improving compositions and methods of vascular injury repair
CN102740894B (en) 2009-08-28 2015-07-15 克利夫兰临床医学基金会 SDF-1 delivery for treating ischemic tissue
HUE053293T2 (en) * 2009-12-11 2021-06-28 Medregen Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
US10813917B2 (en) 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
WO2011082339A2 (en) * 2009-12-31 2011-07-07 Cedars-Sinai Medical Center Regeneration of, reestablishing function in and replacing microvasculature in organs and tissues
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
KR20200016407A (en) 2011-05-16 2020-02-14 젠자임 코포레이션 Use of cxcr4 antagonists
US10662234B2 (en) 2011-06-07 2020-05-26 Mesoblast International Sàrl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
AR087363A1 (en) 2011-07-29 2014-03-19 Pf Medicament USE OF ANTIBODY I-3859 FOR THE DETECTION AND DIAGNOSIS OF CANCERES
AR087364A1 (en) 2011-07-29 2014-03-19 Pf Medicament ANTI-CXCR4 ANTIBODY AND ITS USE FOR CANCERES DETECTION AND DIANOSTIC
US20130231647A1 (en) * 2012-03-05 2013-09-05 BFM Group International GMBH Laser therapy for endogenously enhancing ventricular function
US10072247B2 (en) * 2012-10-05 2018-09-11 Samsung Life Public Welfare Foundation Composition comprising ischemic serum for promoting activation of stem cell and method for promoting activation of stem cell
AU2015256383B2 (en) 2014-05-08 2020-05-21 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
AU2018244776B2 (en) 2017-03-30 2023-12-14 Wake Forest University Health Sciences Methods of treatment for kidney disease
JP7352807B2 (en) 2017-04-12 2023-09-29 マジェンタ セラピューティクス インコーポレイテッド Aryl hydrocarbon receptor antagonists and uses thereof
US11654181B2 (en) 2017-08-11 2023-05-23 Wake Forest University Health Sciences Use of CXCL12 for therapy after prostate surgery
JP7412341B2 (en) 2017-10-31 2024-01-12 エディジーン バイオテクノロジー インコーポレイテッド Compositions and methods for hematopoietic stem and progenitor cell expansion
CA3079404A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
MX2020005878A (en) 2017-12-06 2020-10-07 Magenta Therapeutics Inc Dosing regimens for the mobilization of hematopoietic stem and progenitor cells.
WO2019136159A1 (en) 2018-01-03 2019-07-11 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
KR102056447B1 (en) * 2018-03-16 2019-12-16 (주)메디노 A Method for inducing angiogenesis using neural stem cell
WO2021087406A1 (en) 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
JP2023523334A (en) 2020-04-27 2023-06-02 マジェンタ セラピューティクス インコーポレイテッド Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
EP4308694A1 (en) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US107195A (en) * 1870-09-06 Improvement in sawing-machine
US5008284A (en) 1989-02-15 1991-04-16 E. R. Squibb & Sons, Inc. Method of reducing pre- and post-ischemic myocardial arrhythmias and fibrillation
WO1991002002A1 (en) * 1989-07-21 1991-02-21 Washington University Recombinantly produced human membrane cofactor protein (mcp)
WO1991008231A1 (en) * 1989-11-29 1991-06-13 Brigham And Women's Hospital [Ala IL-8]77 AS A LEUKOCYTE ADHESION INHIBITOR
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
JP2697495B2 (en) * 1991-06-19 1998-01-14 富士レビオ株式会社 Aldehyde derivatives
US5599703A (en) * 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells
JPH07166906A (en) * 1993-12-14 1995-06-27 Nissan Motor Co Ltd Acceleration slip controller by fuel cutting and ignition timing change
DE4442665A1 (en) * 1994-11-30 1996-06-05 Gruenenthal Gmbh Chimeric proteins with fibrinolytic and thrombin-inhibiting properties
US6110889A (en) * 1996-06-14 2000-08-29 Board Of Regents, The University Of Texas System Peptide tumor cell growth inhibitors
JP3866800B2 (en) 1996-08-29 2007-01-10 東菱薬品工業株式会社 Prophylactic and / or therapeutic agent for apoptosis-related diseases
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
EP0897980A3 (en) * 1997-08-20 2002-04-17 Smithkline Beecham Corporation CXCR4B: A human splice variant of CXCR4 chemokine receptor
US5880090A (en) * 1997-09-19 1999-03-09 The Hope Heart Institute Treatment of vascular graft implants with G-CSF
JP4891477B2 (en) * 1997-10-02 2012-03-07 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． Methods for the regulation of angiogenesis and / or development of side arteries and / or other arteries from existing arteriole networks
CN1290353A (en) * 1997-10-06 2001-04-04 阿克丘拉斯有限公司 Methods and apparatus for ablating tissue
AU2559799A (en) * 1998-01-22 1999-08-09 Genentech Inc. Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
EP1060242A4 (en) * 1998-01-23 2003-09-17 Imclone Systems Inc Purified populations of stem cells
AU759603B2 (en) * 1998-02-27 2003-04-17 Trustees Of The University Of Pennsylvania, The Vaccines, immunotherapeutics and methods for using the same
EP1061800A4 (en) * 1998-03-09 2004-10-06 Caritas St Elizabeths Boston Compositions and methods for modulating vascularization
WO1999065507A1 (en) * 1998-06-19 1999-12-23 The General Hospital Corporation Modulating platelet function
US20020107195A1 (en) 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
ATE363293T1 (en) 1999-03-30 2007-06-15 Ran Kornowski INJECTION OF AUTOLOGUE BONE MARROW INTO THE HEART MUSCLE
US20060057722A1 (en) * 1999-03-30 2006-03-16 Myocardial Therapeutics, Inc. Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment
US20060051334A1 (en) * 1999-03-30 2006-03-09 Myocardial Therapeutics, Inc. Injection of bone marrow-derived conditioned medium for angiogenesis
AU6634400A (en) 1999-08-13 2001-03-13 Chiron Corporation Dose of an angiogenic factor and method of administering to improve myocardial blood flow
CA2810249A1 (en) 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
BR0107157A (en) 2000-08-22 2002-07-16 Brigham And Womens Hospital In Diagnosis and treatment of cardiovascular conditions
AU2001288940A1 (en) * 2000-09-08 2002-03-22 The Regents Of The University Of California Gene and sequence variation associated with cancer
WO2002022163A1 (en) * 2000-09-13 2002-03-21 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
US20020094327A1 (en) 2000-11-05 2002-07-18 Petersen Bryon E. Targeting pluripotent stem cells to tissues
IL146970A0 (en) 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
WO2004013158A2 (en) 2002-08-01 2004-02-12 Northwestern University MUTANTS OF IgE PROTEINS AND USES THEREOF
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
WO2008027424A2 (en) * 2006-08-29 2008-03-06 Corning Incorporated High strength substantially non-microcracked cordierite honeycomb body and manufacturing method
US7959387B2 (en) 2007-10-03 2011-06-14 Kennametal Inc. Shrink fit sleeve for tool holder

Also Published As

Publication number Publication date
JP2013063979A (en) 2013-04-11
WO2001094420A1 (en) 2001-12-13
EP2324839A1 (en) 2011-05-25
US8153113B2 (en) 2012-04-10
US20090142296A1 (en) 2009-06-04
US20150150943A1 (en) 2015-06-04
JP2004509847A (en) 2004-04-02
MXPA02012067A (en) 2004-08-19
CA2412436C (en) 2013-05-21
WO2001094420B1 (en) 2002-03-07
US7662392B2 (en) 2010-02-16
JP5414958B2 (en) 2014-02-12
US9387234B2 (en) 2016-07-12
US8486416B2 (en) 2013-07-16
JP2014001221A (en) 2014-01-09
EP1290033B1 (en) 2012-10-31
JP5710574B2 (en) 2015-04-30
US20100209401A1 (en) 2010-08-19
EP1290033A1 (en) 2003-03-12
EP1290033A4 (en) 2004-12-08
EP2324839B1 (en) 2017-08-09
US20040131585A1 (en) 2004-07-08
US20060111290A1 (en) 2006-05-25
JP5710709B2 (en) 2015-04-30
US20080057069A1 (en) 2008-03-06
CA2412436A1 (en) 2001-12-13
CA2810249A1 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
AU2001275339A1 (en) Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
AU2001278010A1 (en) Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
AU8270701A (en) Improvements in and relating to the use of honey in dressings
AU2273601A (en) Storing and recalling information to augment human memories
AU4860900A (en) Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells
IL159895A0 (en) Methods of generating human cardiac cells and tissues and uses thereof
IL209596A0 (en) Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues
AU3947301A (en) The use of plant extracts and sugars to protect keratinous tissue
EP1227821A4 (en) Therapeutic compositions and methods of use thereof
HK1048596A1 (en) Isolation and expansion of human marrow stromal cells
HUP0300917A3 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and pharmaceutical compositions containing them
AU2001270484A1 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
EP1185555A4 (en) Compositions isolated from skin cells and methods for their use
AU2001284135A1 (en) Use of tyramine in cosmetic compositions to lighten the skin
GB0027180D0 (en) Cosmetic and personal care compositions
FR2810540B1 (en) NEW COSMETIC OR HYGIENIC PREPARATIONS IN THE FORM OF DISPERSION
AU2002224471A1 (en) In vivo stimulation of angiogenic activity
AR027898A1 (en) COSMETIC COMPOSITIONS AND METHODS TO CLEAR THE SKIN
AU3501700A (en) Human endokine alpha and methods of use
FR2822700B1 (en) NEW DENTAL HYGIENE PRODUCT IN THE FORM OF NUTRICAMENT UNIDOSE GELIFYING EXTENDED ACTION AND NEW COMPOSITIONS ADAPTED IN COMPRESS OR SEMISOLID GEL
AU2001217686A1 (en) Method of establishing cultures of human dendritic cells and use thereof
AU2001289806A1 (en) Use of beta-mannosylglycerate and derivatives in cosmetic and dermatological formulations
AU2000240061A1 (en) Tissue compositions using cultured fibroblasts and keratinocytes and methods of use thereof
PL352326A1 (en) Noval vegetable genes and use of same
IL145056A0 (en) Expression of human alpha-fetoprotein in mammalian cells